Clinical Cancer Research Meeting Calendar Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tomiyasu, M.
Right arrow Articles by Sugimachi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tomiyasu, M.
Right arrow Articles by Sugimachi, K.
Clinical Cancer Research Vol. 8, 3755-3760, December 2002
© 2002 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Quantification of Macrophage Migration Inhibitory Factor mRNA Expression in Non-Small Cell Lung Cancer Tissues and Its Clinical Significance

Makiko Tomiyasu, Ichiro Yoshino1, Ryuichi Suemitsu, Tatsuro Okamoto and Keizo Sugimachi

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Purpose: Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine derived from T cells and the pituitary gland. However, several types of solid cancers also secrete MIF, and this factor has been suggested to play an important role in carcinogenesis and the progression of malignancy. In this study, we quantified MIF mRNA expression of non-small cell lung cancer tissues and examined its relationship with clinicopathological factors.

Experimental Design: MIF mRNAs of both tumor and normal tissues were quantified by a real-time monitoring reverse-transcription PCR in 59 patients with non-small cell lung cancer. The relationship between the grade of MIF expression and clinicopathological factors such as smoking history, cell type, stage, and prognosis was examined to investigate the clinical significance of intratumoral expression of MIF.

Results: The mean copy number of MIF mRNA per 0.08 µg of total mRNA in tumor tissues was 144,078.00, whereas that of normal lung tissue was 25,438.46 (P < 0.0001). The amounts of MIF proteins revealed by a Western blot analysis correlated well with those of the corresponding mRNAs. Male patients and heavy smokers showed significantly higher expression of MIF. Patients with squamous cell carcinomas showed a higher expression of MIF mRNA than other subjects. In squamous cell carcinoma patients, higher expression of MIF mRNA was significantly associated with unfavorable prognosis (P = 0.0142).

Conclusions: The general intratumoral expression and close relation with smoking suggested that MIF might contribute to tumorigenesis in the lung.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Macrophage MIF2 was first identified as a chemotactic cytokine produced by activated T lymphocytes in 1966 (1 , 2) . In the early 1990s, MIF was established as a proinflammatory cytokine secreted from macrophages and the pituitary gland and a critical mediator of septic shock (3 , 4) . MIF can directly counter-regulate the immunosuppressive effect of glucocorticoids, whereas low concentrations of glucocorticoids have been reported to induce rather than inhibit MIF production from macrophages (5) .

MIF has been reported to be produced not only by macrophages or activated T cells but also by endothelial cells of several organs, including the skin, eye, brain, kidney, and lung (6, 7, 8, 9, 10) . Furthermore, MIF is expressed from early stages in the embryonic chicken lens, suggesting that its expression is strongly correlated with cellular differentiation (11) . In this context, it is considered that MIF may play an important role in various pathophysiological phenomena beyond the immune system.

Chronic inflammatory conditions may affect eventual tumor formation (12 , 13) , although the relationship between inflammation and carcinogenesis at the molecular level remains largely obscure. More recently, Hudson et al. (14) revealed that MIF could overcome p53 activity of growth arrest or apoptosis, and their findings suggested a link between inflammatory condition and carcinogenesis. In another recent study (15) , MIF mRNA and protein were shown to be expressed in melanocytes and melanoma cells, and MIF was shown to enhance the migration and growth of tumor cells and angiogenesis in melanoma tissues. To date, it has been reported that MIF is expressed in several types of tumors, including myelomonocytic leukemia (16) , metastatic prostatic cancer (17) , breast cancer (18) , colon cancer (19) , and lung cancer (20) . However, the precise role of MIF in carcinogenesis and tumor progression remains unclear. In this study, we quantified the MIF mRNA expression of NSCLC tissues and examined its relationship with clinicopathological factors.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Patients.
Between January 1996 and April 2000, 59 Japanese men and women with lung cancer underwent pulmonary resection at the Department of Surgery II, Kyushu University Hospital (Fukuoka, Japan). No patient had received chemotherapy before surgery. Tumor and normal lung tissue samples were obtained from resected specimens, frozen in liquid nitrogen, and stored at -80°C until RNA extraction.

Cultured Cell Lines.
The lung cancer cell lines PC-9 (adenocarcinoma) and A549 (bronchioloalveolar carcinoma) were maintained in continuous culture in RPMI 1640 supplemented with 100 units/ml penicillin-streptomycin and 10% fetal bovine serum. These cells were washed, and cell pellets were collected, frozen in liquid nitrogen, and stored at -80°C until RNA extraction.

Ouantitative RT-PCR.
Gene expression was measured using an ABI Prism 7700 sequence detection system (Perkin-Elmer, Norwalk, CT). Primers and Taqman probes (Custum Oligonucleotide Factory, Foster City, CA) were designed to span exon-intron junctions to prevent amplification of genomic DNA and also to result in amplicons of <150 bp to enhance the efficacy of PCR amplification. Probes were labeled at the 5' end with the reporter dye molecule FAM (6-carboxy-fluorescein; emission {lambda} max = 518 nm) and at the 3' end with the quencher dye molecule TAMARA (6-carboxytetramethyl-rhodamine; emission {lambda} max = 582 nm). Upon amplification, probes annealed to the template are cleaved by the 5' nuclease activity of the Taq polymerase reaction. This process separates the fluorescent label from the quencher and allows the release of 1 unit of fluorescence for each unit amplification. Determining the amount of fluorescence with each cycle, it is possible to determine the number of cycles necessary to reach a certain amount of fluorescence in a test sample compared with known standard amounts of template provided as a standard curve. DNA standards were generated by PCR amplification of gene products, purification, and quantitation by spectrophotometry (absorbance at 260 nm). The number of copies was calculated according to the molecular weight of the gene. Real-time PCRs of cDNA specimens and DNA standards were conducted in a total volume of 50 µl with 1x TaqMan Master Mix (Perkin-Elmer) containing 0.3 µM primers and 0.3 µM probes. Primer sequences were as follows: forward, 5'-CGGACAGGGTCTACATCAA; reverse, 5'-CTTAGGCGAAGGTGGAGTT; and TaqMan, 5'-TACGACATGAACGCGGCCA.

The amplification conditions were 2 min at 50°C, 10 min at 95°C, and 40 cycles of denaturation at 95°C for 15 s and annealing/extension at 60°C for 10 min.

Western Blot Analysis.
The tissue samples of homogenates of the normal lung or primary lung cancer were treated with detergent solution [62.5 mM EDTA, 50 mM Tris (pH 8.0), 0.4% deoxycholic acid, and 1% NP40] and subjected to SDS-PAGE. Proteins on the gel were transferred electrophoretically to a nitrocellulose membrane sheet at 280 mA for 30 min using semidry blotting methods. The sheet was then washed intensively with tris buffered saline and incubated with the polyclonal anti-human MIF antibody (1:1000 dilution) at room temperature for 2 h. After washing with tris buffered saline, the membrane was incubated with peroxidase-conjugated goat antibodies against rabbit IgG at room temperature for 40 min. After the reaction, proteins were visualized with enhanced chemiluminescence Western blotting detection reagents (ECL; Amersham Pharmacia Biotech, Uppsala, Sweden) as recommended in the manufacturer’s protocol. A semiquantification of MIF protein levels was performed by densitometry analysis using NIH Image software.

Statistical Analysis.
For statistical analyses, StatView-J 5.0 software (SAS Institute Inc., Cary, NC) was used. The relationship between MIF expression and clinicopathological factors was examined using Student’s t test. Survival curves were plotted using Kaplan-Meier analysis, and the log-rank test was used to determine statistical differences between life curves.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
MIF mRNA Expression in Lung Cancer Cell Lines and Clinical Lung Cancer Tissues.
RNA was extracted from the lung cancer cell lines (PC-9, QG95, and A549). RT-PCR was performed to detect MIF mRNA. All lung cancer cell lines expressed MIF (Fig. 1)Citation , as determined by sequencing of the MIF amplicon (data not shown). It was thus found that the lung cancer cells readily expressed MIF.



View larger version (47K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. RT-PCR analysis of MIF expression in lung cancer cell lines. MIF amplicons of 75 bp were detected in both.

 
MIF mRNA expression of tumor tissues and corresponding normal tissues from 59 patients was quantified by quantitative RT-PCR. MIF mRNA expression was significantly higher in tumor tissues than in normal tissues (Fig. 2)Citation . The mean copy number of MIF mRNA per 0.08 µg of total mRNA was 144,078.00 in tumor tissues and 25,438.46 in normal tissues, respectively (P < 0.0001). The expression of MIF protein was analyzed by Western blotting and was semi-quantified in four representative cases. Lung cancer tissues expressed MIF protein at a significantly higher level than normal tissues in all four cases tested (Fig. 3A)Citation , and the ratio of tumor:normal tissue in the Western blot almost correlated with that of mRNA (Fig. 3B)Citation .



View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Quantification of MIF mRNA in clinical lung cancer tissues. A significantly higher level of MIF expression was seen in tumor tissue than in the corresponding lung tissue.

 


View larger version (30K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Analysis of MIF protein levels in lung cancer tissues. A, Western blotting analysis for MIF protein. Protein lysates derived from tumor tissues and paired normal lung tisues were subjected to the analyis. A band of Mr 12,500 was observed in each lane. B, comparison of quantitative data of MIF mRNA and protein. The ratios of the amount of MIF mRNA or MIF protein from tumor tissues to those from the corresponding normal lung tissues were calculated by densitometry. {blacksquare}, tumor:normal ratio of MIF protein; {square}, tumor:normal ratio of MIF mRNA.

 
MIF mRNA Expression and Clinicopathological Factors.
Next, we examined the relationship between the level of MIF mRNA and clinicopathological factors (Table 1)Citation . With regard to pack-year index, heavy smokers showed a significantly higher expression of MIF mRNA in tumor tissues (188,827.9 copies) than nonsmokers (83,325.8 copies; P = 0.0316), whereas there were no differences in normal tissues between smokers and nonsmokers. With regard to histology, squamous cell carcinoma tissues showed higher MIF mRNA levels than the other tissue types. The mean values were 205,026.9 copies for squamous cell carcinoma and 125,246.4 copies for adenocarcinoma, respectively (P = 0.0585). Among pathological stages, there were no significant differences in MIF mRNA.


View this table:
[in this window]
[in a new window]

  		Table 1 Relationship between MIF expression and clinicopathological factors

 
MIF Expression and Clinicopathological Factors of Each Cell Type.
In adenocarcinomas, smoking habit and male gender were significantly related to high expression of MIF in tumor tissues, whereas tumor size showed no significant relationship (Table 2)Citation . In squamous cell carcinomas, the relationship between smoking and MIF expression was unclear because all but one of the patients were smokers (Table 3)Citation . With regard to stage, stage I squamous cell carcinomas exhibited significantly lower expression of MIF than stage II-IV carcinomas (P = 0.0283; Table 3Citation ). Stage I adenocarcinomas also exhibited lower expression, although this difference was marginal (P = 0.0709; Table 2Citation ).


View this table:
[in this window]
[in a new window]

  		Table 2 Relationship between intratumoral MIF expression and clinicopathological factors in adenocarcinomas

 

View this table:
[in this window]
[in a new window]

  		Table 3 Relationship between intratumoral MIF expression and clinicopathological factors in squamous cell carcinomas

 
MIF mRNA Expression and Prognosis.
To determine whether there was a relationship between MIF mRNA expression and the prognosis of patients, survival curves were drawn using the Kaplan-Meier method (Fig. 4)Citation . The 5-year survival rate of the high MIF expression group (150,000 copies; n = 22) and low MIF expression group (<150,000 copies; n = 37) was 52.9% and 66.7%, respectively (P = 0.2111). Because MIF mRNA expression differed between squamous cell carcinomas and adenocarcinomas, the survival rate for each of these cell types was also analyzed. In adenocarcinomas, the 5-year survival rates of the high MIF expression group (N = 16) and low MIF expression group (N = 28) were 66.7% and 63.2%, respectively (P = 0.9457; Fig. 5ACitation ). In contrast, the high MIF expression group (N = 6) showed significantly worse prognosis than the low MIF expression group (N = 8) in squamous cell carcinomas (P = 0.0142; Fig. 5BCitation ).



View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Comparison of postoperative survivals among subgroups divided by MIF expression in NSCLC.

 


View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Comparison of postoperative survivals among subgroups divided by MIF expression. A, adenocarcinoma (N = 44); B, squamous cell carcinoma (N = 14).

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In this study, we demonstrated that lung cancer cells produce MIF and provided the first quantification of the amount of MIF mRNA in clinical lung cancer tissues using quantitative RT-PCR. Western blot analysis showed that the copy number of MIF mRNA was almost equal to the amount of MIF protein. Recently, Kamimura et al. (20) first reported that adenocarcinoma of the lung expressed MIF protein and mRNA. They demonstrated by using immunohistochemical analysis and the in situ hybridization technique that intracellular MIF distribution predicts prognosis in patients with adenocarcinoma of the lung. In our quantitative study, lung cancer tissue expressed significantly higher MIF levels than normal tissue, and the higher MIF expression tended to be associated with poor prognosis, especially in patients with squamous cell carcinoma.

With regard to the expression of MIF in tumor cells, Meyer-Siegler et al. (17) reported that MIF mRNA levels in prostatic adenocarcinoma tissues, especially in metastatic lymph nodes, were higher than those in normal prostatic tissues based on the results of a differential display-PCR analysis. It has also been reported that high levels of MIF mRNA and of MIF protein are detected in myelomonocytic leukemia cells (16) and that MIF protein is expressed more highly in human breast ductal carcinoma than in normal breast tissues (18) . Takahashi et al. (19) demonstrated by Western and Northern blot analysis that MIF protein and its mRNA were highly expressed in murine colon carcinomas. These results indicate that MIF is expressed much more highly in a variety of tumor cells than in corresponding normal cells and suggest that this protein may play a critical role in the carcinogenesis of tumor cells or may be induced due to acidotic, ischemic, or other tumor environments.

It has been hypothesized that chronic inflammation causes carcinogenesis from such linkages as infection of Helicobactor pylori and gastric cancer, pyothorax and malignant lymphoma, ulcerative colitis and colon cancer, and reflux esophagitis and esophageal cancer (21) . Recently, Hudson et al. (14) demonstrated that MIF was a key cytokine in the induction proliferative response of mammary cells via suppression of p53 function. Therefore, MIF may play a critical role in the carcinogenesis of such chronic inflammations. However, in our preliminary analysis of the relationship between the expression of p53 and that of MIF mRNA in lung cancer tissues, no significant correlation was observed (data not shown). A more functional evaluation of p53 in vitro may be required to elucidate this issue.

More recently, it was reported that MIF induces degradation of the cyclin-dependent kinase inhibitor p27kip1 through modification of Jab1, which is known as a transcriptional coactivator (22) . In our previous study, reduced expression of p27kip1 was observed in 39% of patients with NSCLC, and the expression status significantly affected the prognosis of patients (23) . Therefore, MIF expression may play a critical role in such mechanisms of reduced p27kip1 expression in lung cancer.

However, conflicting results have also been reported regarding the role of MIF in tumorigenesis. MIF stimulates macrophages to enhance cytotoxicity by the in vitro production of cytokines, such as tumor necrosis factor {alpha} and interleukin 1ß, resulting in inhibition of the growth of tumor cells (24) . Recently, White et al. (25) demonstrated that human macrophages secreted angiogenic CXC chemokines in response to lung cancer cell-derived MIF. Ogawa et al. (26) also reported an important role of MIF in tumorigenesis in a murine model through angiogenic activity and clearly showed that anti-MIF antibody inhibited proliferation of human umbilical vein endothelial cells. We found that T cells isolated from lung cancer tissues secreted substantial levels of MIF protein and mRNA without any in vitro stimulation, but corresponding peripheral blood T cells did not.3 Therefore, such a host reaction might exist, although the clinical significance of its role in the anti-tumor effect is unclear.

In this study, the high expression of MIF mRNA in lung cancer tissues was significantly associated with a heavy smoking habit, although this could not be clearly explained. Smoking is the most important etiological factor in lung cancer and is closely related with male gender and squamous cell carcinoma, which were also associated with high expression of MIF mRNA in this study. Recently, it was accepted that smoking status was significantly correlated with frequency of loss of heterozygosity (27) , which is the main cause of lung carcinogenesis (28 , 29) . Such a genetic disorder might be related to the up-regulation of MIF.

A relationship between gender and MIF expression was clearly seen in this study as well, especially in adenocarcinomas. It is of interest that MIF expression was significantly lower in adenocarcinomas in females, a subpopulation known to have a favorable prognosis (30) . This subpopulation in the present study was also known to have had low exposure to tobacco smoking, and thus it was unclear whether gender or smoking was the causative factor in the high MIF expression.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom requests for reprints should be addressed, at Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka 812-8582, Japan. Phone: 81-92-642-5466; Fax: 81-92-642-5482; E-mail: iyoshino{at}surg2.med.kyushu-u.ac.jp Back

2 The abbreviations used are: MIF, migration inhibitory factor; NSCLC, non-small cell lung cancer; RT-PCR, reverse transcription-PCR. Back

3 H. Baba, I. Yoshimo, M. Tomiyasu, et al., unpublished observations. Back

Received 4/30/02; revised 7/ 8/02; accepted 7/ 8/02.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Bloom B. R., Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science (Wash. DC), 153: 80-82, 1966.[Abstract/Free Full Text]
  2. David J. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc. Natl. Acad. Sci. USA, 56: 72-77, 1996.
  3. Bernhagen J., Calandra T., Mitchell R. A., Martin S. B., Tracey K. J., Voelter W., Manogue K. R., Cerami A., Bucala R. MIF is a pituitary-derived cytokine that potentiates lethal endotoxemia. Nature (Lond.), 365: 756-759, 1993.[CrossRef][Medline]
  4. Calandra T., Bernhagen J., Mitchell R. A., Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med., 179: 1895-1902, 1994.[Abstract/Free Full Text]
  5. Calandra T., Bernhagen J., Metz C. N., Spiegel L. A., Bacher M., Donnelly T., Cerami A., Bucala R. MIF as a glucocorticoid-induced modulator of cytokine production. Nature (Lond.), 377: 68-71, 1995.[CrossRef][Medline]
  6. Shimizu T., Ohkawara A., Nishihira J., Sakamoto W. Identification of macrophage migration inhibitory factor (MIF) in human skin and its immunohistochemical localization. FEBS Lett., 381: 199-202, 1996.[CrossRef][Medline]
  7. Matsuda A., Tagawa Y., Yoshida K., Matsuda H., Nishihara J. Identification and immunohistochemical localization of macrophage migration inhibitory factor in human cornea. FEBS Lett., 385: 225-228, 1996.[CrossRef][Medline]
  8. Ogata A., Nishihara J., Suzuki T., Nagashima K., Tashiro K. Identification of macrophage migration inhibitory factor (MIF) mRNA expression in neural cells of the rat brain by in situ hybridization. Neurosci. Lett., 249: 173-177, 1998.
  9. Imamura K., Nishihara J., Suzuki M., Yasuda K., Sasaki S., Kusunoki Y. Identification and immunohistochemical localization of macrophage migration inhibitory factor in human kidney. Biochem. Mol. Biol. Int., 40: 1233-1242, 1996.[Medline]
  10. Donnelly S. C., Haslett C., Reid P. T., Grant I. S., Wallace W. A. H., Metz C. N., Bruce L. J., Bucala R. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat. Med., 3: 320-323, 1997.[CrossRef][Medline]
  11. Wistow G. J., Shaughnessy M. P., Lee D. C., Hodin J., Zalenka P. S. A macrophage migration inhibitory factor is expressed in the differentiation cells of the eye lens. Proc. Natl. Acad. Sci. USA, 90: 1272-1275, 1993.[Abstract/Free Full Text]
  12. Gordon L. I., Weitzman S. A. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood, 76: 655-663, 1990.[Abstract/Free Full Text]
  13. Christen S., Hagen T. M., Shigehara M. K., Ames B. N. Chronic infection and inflammation leads to cancer Parsonnet J. Horning S. eds. . Microbes and Malignancy: Infection as a Cause of Cancer, 35-88, Oxford University Press Oxford 1999.
  14. Hudson J. D., Shoaibi M. A., Maestro R., Carnero A., Hannon G. J., Beach D. H. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med., 190: 1375-1382, 1999.[Abstract/Free Full Text]
  15. Shimizu T., Abe R., Nakamura H., Ohkawara A., Suzuki M., Nishihira J. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem. Biophys. Res. Commun., 264: 751-758, 1999.[CrossRef][Medline]
  16. Nishihira J., Koyama Y., Mizue Y. Identification of macrophage migration inhibitory factor in human leukemia HL-60 cells and its induction by lipopolysaccharide. Biochem. Mol. Biol. Int., 40: 861-869, 1996.[Medline]
  17. Meyer-Siegler K., Hudson P. B. Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology, 48: 448-452, 1996.[CrossRef][Medline]
  18. Bini L., Mgi B., Marzocchi B., Arcuri F., Tripodi S., Cintorino M. Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis, 18: 2832-2841, 1997.[CrossRef][Medline]
  19. Takahashi N., Nishihara J., Sato Y., Kondo M., Ogawa H., Ohshima T. Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol. Med., 4: 707-714, 1998.[Medline]
  20. Kamimura A., Kamachi M., Nishihira J., Ogura S., Isobe H., Dosaka-Akita H., Shindoh M., Ohbuchi T., Kawakami Y. Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer (Phila.), 89: 334-341, 2000.[CrossRef][Medline]
  21. Cordon C. C., Prives C. At the crossroads of inflammation and tumorigenesis. J. Exp. Med., 190: 1367-1370, 1999.[Free Full Text]
  22. Kleemann R., Hausser A., Geiger G., Mischke R., Burger K. A., Flieger O., Johannes F. J., Roger T., Calandra T., Kapurniotu A., Grell M., Finkelmeier D., Brunner H., Bernhagen J. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature (Lond.), 408: 211-216, 2000.[CrossRef][Medline]
  23. Tsukamoto S., Sugio K., Sakada T., Ushijima C., Yamazaki K., Sugimachi K. Reduced expression of cell-cycle regulator p27kip1 correlates with a shortened survival in non-small cell lung cancer. Lung Cancer, 34: 83-90, 2001.[CrossRef][Medline]
  24. Pozzi L. A., Weiser W. Y. Human recombinant migration inhibitory factor activates human macrophages to kill tumor cells. Cell. Immunol., 145: 372-379, 1992.[CrossRef][Medline]
  25. White E. S., Strom S. R. B., Wys N. L., Arenberg D. A. Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. J. Immunol., 166: 7549-7555, 2001.[Abstract/Free Full Text]
  26. Ogawa H., Nishihara J., Sato Y., Knodo M., Takahashi N., Oshima T., Todo S. An antibody for macrophage migration inhibitory factor suppresses tumor growth and inhibits tumor-associated angiogenesis. Cytokine, 12: 309-314, 2000.[CrossRef][Medline]
  27. Wistuba I. I., Lam S., Behrens C., Virmani A. K., Fong K. M., LeRiche J., Samet J. M., Srivastava S., Minna J. D., Gazder A. F. Molecular damage in the bronchial epithelium of current and former smokers. J. Natl. Cancer Inst. (Bethesda), 89: 1366-1373, 1997.[Abstract/Free Full Text]
  28. Mao L., Lee J. S., Kurie J. M., Fan Y. H., Lippman S. M., Lee J. J., Ro J. Y., Broxson A., Yu R., Morice R. C., Kemp B. L., Khuri F. R., Walsh G. L., Hittelman W. N., Hong W. K. Clonal genetic alterations in the lungs of current and former smokers. J. Natl. Cancer Inst. (Bethesda), 89: 857-862, 1997.[Abstract/Free Full Text]
  29. Fong K. M., Zimmerman P. V., Smith P. J. Correlation of loss of heterozygosity at 11p with tumor progression and survival in non-small cell lung cancer. Genes Chromosomes Cancer, 10: 183-189, 1994.[Medline]
  30. Yoshino I., Baba H., Fukuyama S., Kameyama T., Shikada Y., Tomiyasu M., Suemitsu R. A time trend of profile and surgical results in 1123 patients with non-small cell lung cancer. Surgery (St. Louis), 131: 242-248, 2002.



This article has been cited by other articles:


Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
L. M. Marsh, L. Cakarova, G. Kwapiszewska, W. von Wulffen, S. Herold, W. Seeger, and J. Lohmeyer
Surface expression of CD74 by type II alveolar epithelial cells: a potential mechanism for macrophage migration inhibitory factor-induced epithelial repair
Am J Physiol Lung Cell Mol Physiol, March 1, 2009; 296(3): L442 - L452.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. McClelland, L. Zhao, S. Carskadon, and D. Arenberg
Expression of CD74, the Receptor for Macrophage Migration Inhibitory Factor, in Non-Small Cell Lung Cancer
Am. J. Pathol., February 1, 2009; 174(2): 638 - 646.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. M. Coleman, B. E. Rendon, M. Zhao, M.-W. Qian, R. Bucala, D. Xin, and R. A. Mitchell
Cooperative Regulation of Non-Small Cell Lung Carcinoma Angiogenic Potential by Macrophage Migration Inhibitory Factor and Its Homolog, D-Dopachrome Tautomerase
J. Immunol., August 15, 2008; 181(4): 2330 - 2337.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. E. Rendon, T. Roger, I. Teneng, M. Zhao, Y. Al-Abed, T. Calandra, and R. A. Mitchell
Regulation of Human Lung Adenocarcinoma Cell Migration and Invasion by Macrophage Migration Inhibitory Factor
J. Biol. Chem., October 12, 2007; 282(41): 29910 - 29918.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
I. Yoshino, D. Kawano, T. Oba, K. Yamazaki, T. Kometani, and Y. Maehara
Smoking Status as a Prognostic Factor in Patients with Stage I Pulmonary Adenocarcinoma
Ann. Thorac. Surg., April 1, 2006; 81(4): 1189 - 1193.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Fingerle-Rowson, O. Petrenko, C. N. Metz, T. G. Forsthuber, R. Mitchell, R. Huss, U. Moll, W. Muller, and R. Bucala
The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting
PNAS, August 5, 2003; 100(16): 9354 - 9359.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tomiyasu, M.
Right arrow Articles by Sugimachi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tomiyasu, M.
Right arrow Articles by Sugimachi, K.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online